强生前列腺癌三期研究显示:手术前后使用Erleada®(阿帕鲁胺)显著降低转移或死亡风险,打破数十年治疗范式

美股速递
May 31

强生公司公布的前列腺癌三期临床试验结果显示,在手术前后联合使用其药物Erleada®(阿帕鲁胺),能够显著降低患者发生癌症转移或死亡的风险。这一突破性发现,标志着对数十年来既定治疗范式的重大革新。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10